The final in a series on the need to formally prioritise patient input in HTA decision-making, we argue that the system currently lacks the ethical framework necessary to make morally defensible decisions. No system of decision-making can be considered ethical when its rules, when properly applied, lead to outcomes that delay access to treatment with consequent suffering, harm, and in some cases, death.
If the system properly applied results in harm, then the problem is worse than we think
November 20, 2025 Latest NewsBioPharmaCommentNews of the Day
Latest Video
New Stories
-
Peter Mac taps Sydney manufacturer to test its solid tumour CAR T therapy
October 14, 2026 - - Latest News -
Priceline Pharmacy puts its name on the Diamonds as netball rides record growth
October 14, 2026 - - Latest News -
'Maximising off patent medicines and why the PBS needs a biosimilar strategy'
October 14, 2026 - - Latest News -
Until the law changes what the committee is instructed to weigh, these processes will deliver nothing
October 14, 2026 - - Latest News -
The PBS stands alone as the only major health and disability program going backwards
October 13, 2026 - - Latest News -
GBMA's Nikki Lorenz returns from global generics talks with WHO and WTO
October 13, 2026 - - Latest News -
Australian children with cancer are missing out on trials adults can access
October 13, 2026 - - Latest News
